MENLO PARK, CA & INDIANAPOLIS–(BUSINESS WIRE)–Indianapolis-based Community Health Network and GRAIL, LLC, a healthcare company whose mission is to find cancer early when it can be cured, today announced a partnership to provide in Galleria®, GRAIL’s Multi-Cancer Early Detection (MCED) blood test, to people at Community Health Network care sites. Community Health Network, central Indiana’s leading integrated health system with more than 200 care sites, will be the first health system to offer the Galleri test to patients in its region.
Through this partnership, the Community Health Network will provide the Galleri test to people at high risk for cancer, including those over the age of 50. The test will be offered to eligible individuals through their primary care providers at select Community Health Network sites in addition to existing one-time cancer screenings.
“As a health network committed to exceptional patient care, and with the generous support of the Community Health Network Foundation, we are thrilled to be the first health system in central Indiana to provide the test. Galleri to patients as part of the full continuum of our service network,” said Patrick McGill, MD, Executive Vice President and Chief Transformation Officer of the Community Health Network. “MCED tests like Galleri represent cutting-edge innovation that, when combined with proper screenings and care, can give patients diagnosed with cancer in our communities the best chance of success.
The Galleri test is a unique MCED blood test. In a clinical study, Galleri’s test has been shown to detect a common signal of more than 50 types of cancers, more than 45 of which today miss recommended screening tests. Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which can then guide the diagnostic workup. Early detection of cancer can improve cancer outcomes, but today many cancers are detected at advanced stages because only five types of cancer have been recommended for screenings – breast, cervical, colon, lung and prostate.
“Healthcare systems are increasingly looking for ways to better meet patient needs, and the Galleri test – which can be administered with a simple blood draw as an adjunct to other cancer screenings – has the potential to screen more of cancers at earlier stages when there is a better chance of successful treatment,” said Bob Ragusa, CEO of GRAIL. “The status quo in cancer screening is simply unacceptable and using Galleri to complement existing screening approaches offers the potential to improve cancer detection in the population and improve public health.
About the Community Health Network
Based in Indianapolis, Community Health Network has been deeply committed to the communities it serves since opening its first hospital, Community Hospital East, in 1956. Community Health Network puts patients first while providing a full continuum of health care services. health, world-class innovations and a new focus on population health management. Exceptional care, simply delivered, is what sets Community Health Network apart and makes it a leading nonprofit healthcare destination in central Indiana. For more information on the Community Health Network, please visit eCommunity.com.
The earlier the cancer is detected, the higher the chances of success. Galleri’s Multi-Cancer Early Detection Test can detect signals in more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the origin of the cancer signal, or the location of the cancer in the body, with high accuracy to help guide the next steps in diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) testing, or cancer screening of the cervix. It is intended for use in people at high risk of cancer, such as people aged 50 or over.
For more information about Galleri, visit galleryi.com.
GRAIL is a healthcare company whose mission is to find cancer early, when it can be cured. GRAIL is focused on alleviating the global cancer burden by developing pioneering technology to detect and identify multiple types of deadly cancers early. The company uses the power of next-generation sequencing, population-scale clinical studies, and cutting-edge computing and data science to improve scientific understanding of cancer biology and to develop its multi-cancer early detection blood. test. GRAIL is headquartered in Menlo Park, CA, with offices in Washington, DC, North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN) currently held separately from Illumina Inc. pursuant to the European Commission’s Interim Measures Order dated October 29, 2021.
For more information, visit grail.com.
Important Safety Information
Galleri’s test is recommended for use in adults at high risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare professional. Galleri is intended to detect cancer signals and predict where the cancer signal is located in the body. The use of Galleri is not recommended in people who are pregnant, aged 21 or younger or who are undergoing active cancer treatment.
Results should be interpreted by a healthcare professional in the context of medical history, clinical signs and symptoms. A test result of “cancer signal not detected” does not rule out cancer. A “Cancer Signal Detected” test result requires confirmatory diagnostic evaluation by medically established procedures (eg, imaging) to confirm cancer.
If the cancer is not confirmed by additional tests, it could mean that there is no cancer or that the tests were insufficient to detect the cancer, especially because the cancer is located in another part of the body . False positive (cancer signal detected in the absence of cancer) and false negative (cancer signal not detected in the absence of cancer) test results occur. Rx only.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics determined by GRAIL. The Galleri test has not been cleared or approved by the United States Food and Drug Administration. GRAIL’s clinical laboratory is regulated by the CLIA to perform high complexity testing. The Galleri test is intended for clinical purposes.